Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | RBP4 | P02753 | 2/20 | 0.39 |
| ▸ | LIPE | Q05469 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461632 | 1.00 | TACR1 (0.45) | TACR1PDE4BRORCUSP30RBP4 | |
| SCHEMBL4475295 | 0.89 | RORC (0.42) | TACR1PDE4BRORCUSP30RBP4 | |
| SCHEMBL4475292 | 0.89 | RORC (0.42) | TACR1PDE4BRORCUSP30RBP4 | |
| SCHEMBL4472653 | 0.84 | PDE4B (0.48) | TACR1PDE4BRORCUSP30RBP4 | |
| SCHEMBL4472649 | 0.84 | PDE4B (0.48) | TACR1PDE4BRORCUSP30RBP4 | |
| SCHEMBL4465368 | 0.78 | FAAH (0.43) | RORCRBP4TDP1HTTL3MBTL1 | |
| SCHEMBL16780215 | 0.77 | RORC (0.51) | TACR1PDE4BRORCUSP30 | |
| SCHEMBL13858400 | 0.77 | RORC (0.51) | TACR1PDE4BRORCUSP30 | |
| SCHEMBL16780217 | 0.77 | RORC (0.51) | TACR1PDE4BRORCUSP30 | |
| SCHEMBL23924226 | 0.76 | PDE4B (0.48) | TACR1PDE4BRORCUSP30LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572805-B2 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | HTR2B, OPRD1, HTR1B | TACR1 59/4885PDE4B 592/4885RORC 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.